Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai’s Ontak sBLA Granted U.S. FDA Approval

This article was originally published in PharmAsia News

Executive Summary

TOKYO - U.S. FDA granted full approval to Eisai's biologic Ontak (denileukin) for intravenous injection for treating a recurrent type of lymph node cancer, cutaneous T-cell lymphoma in patients whose malignant cells express the CD25 component of the interleukin-2 receptor

You may also be interested in...



Eisai Expands Oncology Pipeline With SymBio Lymphoma Treatment

TOKYO - Eisai has signed a licensing agreement with Japanese start-up SymBio Pharmaceuticals to jointly develop and commercialize lymphoma treatment bendamustine (SyB L-0501) in Japan

Case Study: Eisai Partners With Swedish Startup BioArctic In Search Of Cure For Alzheimer’s Disease (Part 2 Of 2)

Eisai has taken an aggressive approach in seeking out the right partners to fill out its pipelines. The company's partnership with Swedish startup BioArctic to develop a drug for Alzheimer's disease is no exception. Eisai and BioArctic discussed the beginnings of their partnership in the first part of this case study (PharmAsia News, Aug. 6, 2008). This second section discusses in greater detail why the companies view the partnership as a success and what each has brought to the other.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

ID043835

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel